Mood disorders in early Parkinson's disease

Current Opinion in Psychiatry

Volumn 17, Issue 3, 2004, Pages 191-196

  Müller, Thomas ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Anhedonia; Diagnosis; Mood; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; DESIPRAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIPRAMINE; LEVODOPA; NEUROPROTECTIVE AGENT; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR; BRAIN FUNCTION; BRAIN REGION; CAREGIVER; CLINICAL FEATURE; COGNITION; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; MOOD; MOOD DISORDER; NERVE DEGENERATION; NEUROPROTECTION; PARKINSON DISEASE; PREMOTOR CORTEX; REVIEW;

EID: 2342479113     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200405000-00007     Document Type: Review

References (48)

1. Horowski R, Horowski L, Vogel S, et al. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurology 1995; 45:565-568.
2. Humboldt Wv: Letters to a girlfriend [in German]. Lindner J, editor. Berlin: Verlag der Nation; 1986.
3. Parkinson J. An Essay on the shaking Palsy. London: Sherwood Neely and Jones; 1817.
4. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999; 28:35-38.
5. Cote L. Depression: impact and management by the patient and family. Neurology 1999; 52 (suppl 3):S7-S9.
6. Müller T, Voss B, Hellwig K, Przuntek H. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. NeuroRehabilitation 2003; 18:271-275.
7. Bernheimer H, Birkmayer W, Hornykiewicz O. Distribution of 5-hydroxytryptamine (serotonin) in the human brain and ita behavior in patients with Parkinson's syndrome [in German]. Klin Wochenschr 1961; 39:1056-1059.
8. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia [in German]. Wien Klin Wochenschr 1961; 73:787-788.
9. Foley P, Mizuno Y, Nagatau T, et al. The L-DOPA story: an early Japanese contribution. Parkinsonism Related Disord 2000; 6:1.
10. Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997; 21:393-400.
11. Doder M, Rabiner EA, Turjanski N, et al. Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. Neurology 2003; 60:601-805. This report shows the impact of serotonin on tremor with functional imaging techniques.
12. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110:517-536. This review provides a new and revolutionary neuropathological view of the onset and progreasion of Parkinson's disease.
13. Birkmayer W, Danielczyk W, Neumayer E, Riederer P. The balance of biogenic amines as condition for normal behaviour. J Neural Transm 1972; 33:163-178.
14. Braak H, Braak E, Yilmazer D, et al. Nigral and extranigral pathology in Parkinson's dsease. J Neural Transm Suppl 1995; 46:15-31.
15. Burn DJ. Depression in Parkinson's disease. Eur J Neurol 2002; 9(suppl 3):44-54. This comprehensive review has a focus on treatment of depression in Parkinson's disease.
16. Henderson JM, Lu Y, Wang S, et al. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J Neurol Neurosurg Psychiatry 2003; 74:956-958.
17. Hilker R, Razai N, Ghaemi M, et al. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 2003; 105:262-269.
18. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15:669-677.
19. Taylor AE, Saint-Cyr JA, Lang AE, Kenny FT. Parkinson's disease and depression. A critical re-evaluation. Brain 1986; 109 (Pt 2):279-292.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J Neurol Neurosurg Psychiatry 1992; 55:181-184.
22. Müller T, Schafer S, Kuhn W, Przuntek H. Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 2000; 27:311-315.
23. Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl 1999; 56:31-74.
24. Gale C, Martyn C: Tobacco, coffee, and Parkinson's disease. BMJ 2003; 326:561-562.
25. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001; 18:797-806.
26. Bum DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. Mov Disord 2002; 17:445-454. A comprehensive review on depression in various stages of Parkinson's disease is presented.
27. Fox MJ. Lucky man: a memoir. New York: Hyperion; 2003. A remarkable book on life with Parkinson's disease.
28. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40:1529-1534.
29. Starkstein SE, Petracca G, Chemerinski E, et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 1998; 13:29-33.
30. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56:1712-1721.
31. Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999; 6:141-150.
32. Jellinger KA. Post mortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56:1-29.
33. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68:423-428.
34. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's dsease. Clin Neuropharmacol 2003; 26:109-111.
35. Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000; 61:127-132.
36. Mattox JH, Buckman MT, Bernstein J, et al. Dopamine agonists for reducing depression associated with hyperprolactinemia. J Reprod Med 1986; 31:694-698.
37. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:399-406. This report provides some evidence on the antidepressant potency of dopamine agonists.
38. Mayeux R. The 'serotonin hypothesis' for depression in Parkinson's disease. Adv Neurol 1990; 53:163-166.
39. Corrigall MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placabo in patients with major depression. Depress Anxiety 2000; 11:58-65.
40. Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000; 12:137-140.
41. Zangen A, Nakash R, Overstreet DH, Yadid G. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology (Berl) 2001; 155:434-439.
42. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995; 45:1757-1760.
43. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the 'on-off phenomenon in Parkinson's disease. Psychol Med 1987; 17:899-904.
44. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12:192-214.
45. Leo RJ, Lichter DG, Hershey LA. Parkinsonism associated with fluoxetine and cimetidine: a case report. J Geriatr Psychiatry Neurol 1995; 8:231-233.
46. Durif F. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging 1999; 14:337-345.
47. Ekesbo A, Rydin E, Torstenson R, et al. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999; 52:120-125.
48. Di Rocco A, Brannan T, Prikhojan A, Yahr MD. Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 1998; 105:247-251.